MA41375A - Anticorps igg bispécifiques et leurs procédés de préparation - Google Patents

Anticorps igg bispécifiques et leurs procédés de préparation

Info

Publication number
MA41375A
MA41375A MA041375A MA41375A MA41375A MA 41375 A MA41375 A MA 41375A MA 041375 A MA041375 A MA 041375A MA 41375 A MA41375 A MA 41375A MA 41375 A MA41375 A MA 41375A
Authority
MA
Morocco
Prior art keywords
igg antibodies
preparation processes
bispecific igg
bispecific
processes
Prior art date
Application number
MA041375A
Other languages
English (en)
Inventor
Hector Aldaz
Shane Atwell
Stephen J Demarest
Karen J Froning
Brian Arthur Kuhlman
Andrew Philip Leaver-Fay
Original Assignee
Lilly Co Eli
Univ North Carolina Chapel Hill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli, Univ North Carolina Chapel Hill filed Critical Lilly Co Eli
Publication of MA41375A publication Critical patent/MA41375A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA041375A 2015-01-22 2016-01-20 Anticorps igg bispécifiques et leurs procédés de préparation MA41375A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562106494P 2015-01-22 2015-01-22

Publications (1)

Publication Number Publication Date
MA41375A true MA41375A (fr) 2017-11-28

Family

ID=55358122

Family Applications (1)

Application Number Title Priority Date Filing Date
MA041375A MA41375A (fr) 2015-01-22 2016-01-20 Anticorps igg bispécifiques et leurs procédés de préparation

Country Status (5)

Country Link
US (2) US10774156B2 (fr)
EP (1) EP3247721B1 (fr)
ES (1) ES3031036T3 (fr)
MA (1) MA41375A (fr)
WO (1) WO2016118742A1 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10047167B2 (en) * 2013-03-15 2018-08-14 Eli Lilly And Company Methods for producing fabs and bi-specific antibodies
MA45554A (fr) 2016-07-01 2019-05-08 Resolve Therapeutics Llc Fusions de binucléase optimisées.
US11820828B2 (en) 2016-12-22 2023-11-21 Eli Lilly And Company Methods for producing fabs and IgG bispecific antibodies
EP3589650A1 (fr) 2017-03-02 2020-01-08 Novartis AG Protéines hétérodimères modifiées
US20200155702A1 (en) 2017-06-16 2020-05-21 Eli Lilly And Company Engineered Antibody Compounds and Conjuates Thereof
CN111315767B (zh) 2017-08-22 2025-03-18 萨纳生物有限责任公司 可溶性干扰素受体及其用途
CN111448217A (zh) 2017-12-22 2020-07-24 阿根思公司 双特异性抗原结合构建体
GB201802487D0 (en) 2018-02-15 2018-04-04 Argenx Bvba Cytokine combination therapy
WO2019199916A1 (fr) * 2018-04-13 2019-10-17 Eli Lilly And Company Anticorps trispécifiques à base de fab
TWI722535B (zh) 2018-08-21 2021-03-21 美商美國禮來大藥廠 測定蛋白質或肽濃度的方法及其用途
US20220176011A1 (en) * 2019-02-18 2022-06-09 Lankenau Institute For Medical Research Scar reducing wound closure materials
EP3966238A2 (fr) * 2019-05-09 2022-03-16 Merus N.V. Domaines variants pour la multimérisation de protéines et leur séparation
CA3149939A1 (fr) 2019-09-06 2021-03-11 Stephen J. Demarest Proteines comprenant des domaines constants de recepteur de lymphocytes t
JP7664943B2 (ja) 2020-03-25 2025-04-18 イーライ リリー アンド カンパニー 多重特異性結合タンパク質およびそれを開発する方法
US20250223379A1 (en) * 2021-01-11 2025-07-10 Adimab, Llc Variant ch3 domains engineered for preferential ch3 heterodimerization, multi-specific antibodies comprising the same, and methods of making thereof
CN114106192B (zh) * 2021-12-20 2024-06-14 广州爱思迈生物医药科技有限公司 双特异性抗体及其应用
US20250064958A1 (en) 2023-08-22 2025-02-27 Eli Lilly And Company AMYLOID PRECURSOR PROTEIN (APP) RNAi AGENTS
IL327830A (en) 2023-10-18 2026-06-01 Lilly Co Eli Transferrin receptor binding proteins and uses thereof
WO2025166111A1 (fr) 2024-02-02 2025-08-07 Eli Lilly And Company Conjugués comportant une protéine de liaison au récepteur de la transferrine
TW202547525A (zh) 2024-02-02 2025-12-16 美商美國禮來大藥廠 SARM1 RNAi藥劑
WO2025224084A1 (fr) 2024-04-22 2025-10-30 Engimmune Therapeutics Ag Protéines comprenant des domaines constants du récepteur des lymphocytes t
WO2025250605A1 (fr) 2024-05-31 2025-12-04 Eli Lilly And Company Agents d'interférence d'arn acvr2a et acvr2b
WO2025264602A1 (fr) 2024-06-18 2025-12-26 Eli Lilly And Company Agents d'arni de prnp
US20260083854A1 (en) 2024-09-25 2026-03-26 Eli Lilly And Company Conjugates comprising bis-mspt linker
WO2026080661A1 (fr) 2024-10-10 2026-04-16 Eli Lilly And Company Agents d'arn interférence de sod1

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US573168A (en) 1896-12-15 silberman
US7754208B2 (en) * 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
ME01803B (fr) 2004-08-05 2010-12-31 Genentech Inc Antagonistes anti-cmet humanises
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
EA015992B1 (ru) 2006-03-17 2012-01-30 Байоджен Айдек Эмэй Инк. Стабилизированное антитело и многовалентная антигенсвязывающая молекула на его основе, способы получения и использования вышеназванного стабилизированного антитела
WO2007147901A1 (fr) 2006-06-22 2007-12-27 Novo Nordisk A/S Production d'anticorps bispécifiques
EP2626372B1 (fr) 2007-03-29 2018-03-21 Genmab A/S Anticorps bispécifiques et procédés de production de ceux-ci
EP2234641B1 (fr) * 2008-01-03 2015-08-19 Genmab A/S Anticorps monoclonaux anti-cd32b
EP3663318A1 (fr) 2008-01-07 2020-06-10 Amgen Inc. Procédé de fabrication de molécules hétérodimères fc d'anticorps utilisant les effets de conduite électrostatique
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
EP2580243B1 (fr) * 2010-06-09 2019-10-16 Genmab A/S Anticorps dirigés contre le cd38 humain
CN103429620B (zh) 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
JP2014511836A (ja) 2011-03-25 2014-05-19 グレンマーク ファーマシューティカルズ， エセ．アー． ヘテロ二量体免疫グロブリン
WO2013033008A2 (fr) 2011-08-26 2013-03-07 Merrimack Pharmaceuticals, Inc. Anticorps bispécifiques à fc en tandem
US9574010B2 (en) 2011-11-04 2017-02-21 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the Fc domain
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
US9914785B2 (en) 2012-11-28 2018-03-13 Zymeworks Inc. Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
US10047167B2 (en) 2013-03-15 2018-08-14 Eli Lilly And Company Methods for producing fabs and bi-specific antibodies
TW201517916A (zh) 2013-03-15 2015-05-16 Lilly Co Eli Ｖｅｇｆｒ１抗體之治療用途
WO2014154254A1 (fr) 2013-03-26 2014-10-02 Nokia Solutions And Networks Oy Méthode et appareil
EP3174897B1 (fr) * 2014-07-29 2020-02-12 F.Hoffmann-La Roche Ag Anticorps multi-spécifiques
CN108290958B (zh) * 2015-10-02 2021-12-28 豪夫迈·罗氏有限公司 多特异性抗体
US11820828B2 (en) * 2016-12-22 2023-11-21 Eli Lilly And Company Methods for producing fabs and IgG bispecific antibodies
EP3589650A1 (fr) * 2017-03-02 2020-01-08 Novartis AG Protéines hétérodimères modifiées
AR112341A1 (es) * 2017-08-02 2019-10-16 Lilly Co Eli ANTICUERPOS BIESPECÍFICOS ANTI-TNF- / ANTI-IL-23 DE IgG
WO2019199916A1 (fr) * 2018-04-13 2019-10-17 Eli Lilly And Company Anticorps trispécifiques à base de fab

Also Published As

Publication number Publication date
EP3247721B1 (fr) 2025-05-07
US11976136B2 (en) 2024-05-07
US20210054103A1 (en) 2021-02-25
EP3247721A1 (fr) 2017-11-29
ES3031036T3 (en) 2025-07-03
US10774156B2 (en) 2020-09-15
US20180009908A1 (en) 2018-01-11
WO2016118742A1 (fr) 2016-07-28

Similar Documents

Publication Publication Date Title
FR24C1023I2 (fr) Anticorps thérapeutiques et leurs utilisations
FR25C1022I2 (fr) Anticorps anti-pd-1
MA43389A (fr) Anticorps anti-ox40 et leurs procédés d'utilisation
MA49687A (fr) Anticorps anti-ctla-4 et leurs utilisations
MA42935A (fr) Anticorps bispécifiques anti-cd3 optimisés et leurs utilisations
EP3389699A4 (fr) Anticorps monoclonaux chimériques et humanisés anti-ctla4 humaine, et leurs utilisations
MA43955A (fr) Anticorps anti-bcma et anti-cd3 bispécifiques de format bite
EP3377102C0 (fr) Anticorps anti-pd-1 et leurs utilisations thérapeutiques
EP3328895A4 (fr) Anticorps anti-pd-l1 et leurs utilisations
EP3426686A4 (fr) Anticorps anti-pacap humanisés et leurs utilisations
EP3334824A4 (fr) Anticorps anti-pd-1
MA53184A (fr) Anticorps anti-ox40 et leurs utilisations
MA50949A (fr) Anticorps anti-ctla-4 et leurs procédés d'utilisation
EP3387442A4 (fr) Anticorps anti-cd73 humanisés
MA53355A (fr) Anticorps anti-ctla-4 et leurs procédés d'utilisation
MA49537A (fr) Anticorps anti-lag3 et leurs utilisations
EP3507307A4 (fr) Anticorps bispécifiques
EP3386536A4 (fr) Composition de conjugués d'agonistes-constructions d'anticorps et leurs procédés d'utilisation
MA42626A (fr) Nouveaux anticorps anti-pd-1
EP3316909A4 (fr) Anticorps anti-ntb-a ainsi que compositions et procédés associés
EP3397276A4 (fr) Anticorps et conjugués de ceux-ci
EP3363816A4 (fr) Anticorps anti-ox40 et son application
EP3441086A4 (fr) Anticorps monoclonal anti-pd-1
EP3383904A4 (fr) Anticorps ctla-4 et leurs utilisations
EP3383915A4 (fr) Anticorps anti-pd-1